News Chugai Pharmaceutical Co., Ltd.

Equities

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 18/02/2026 GMT			5-day change	1st Jan Change
9,400.00 ^JPY	+2.51%		+2.17%	+14.04%

02-06	Japan's Nikkei rallies on earnings in unsteady trade before Sunday election	RE
02-06	Japanese drugmakers slump after Trump unveils discount drug website	RE

All News

02-09	Chugai Pharmaceutical : NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period	PU
02-06	Japan's Nikkei rallies on earnings in unsteady trade before Sunday election	RE
02-06	Japanese drugmakers slump after Trump unveils discount drug website	RE
01-30	Chugai Announces 2025 Full Year Results and Forecasts for 2026	AQ
01-30	Chugai Relocates Head Office	AQ
01-30	Chugai Pharmaceutical Co., Ltd. - Revision of the Stock Compensation System	AQ
01-29	Chugai Pharmaceutical Co., Ltd., 2025 Earnings Call, Jan 29, 2026
01-29	Chugai Pharmaceutical's Profit Climbs 12% in 2025	MT
01-29	Chugai Pharmaceutical Co., Ltd. Proposes Year-End Dividend for the Fiscal Year Ended December 31, 2025, Effective March 27, 2026	CI
01-29	Chugai Pharmaceutical Co., Ltd. Proposes Special Dividend for the Fiscal Year Ended December 31, 2025, Effective March 27, 2026	CI
01-29	Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year End Fiscal Year Ending December 31, 2026	CI
01-29	Chugai Pharmaceutical : Full Year Results (Jan-Dec 2025)	PU
01-29	Chugai Pharmaceutical : Supplementary Materials Supplementary Materials	PU
01-29	Chugai Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-28	Chugai Pharmaceutical : Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer	PU
01-28	Chugai Pharmaceutical : Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer	PU
01-26	Chugai Targets 2028 Approval For Obesity Drug	MT
01-22	Protara Therapeutics, Inc. to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of Tara-002 in BCG-Unresponsive NMIBC Patients at the Asco Genitourinary Cancers Symposium	CI
01-15	Chugai Pharmaceutical : Presentation	PU
01-12	Chugai Receives Tokyo Governor Prize for Corporate Governance of the Year 2025	AQ
12-30	Chugai Completes Merger With Renalys Pharma	MT
12-29	Chugai Pharmaceutical Co., Ltd. completed the acquisition of Renalys Pharma.	CI
12-28	Final dividend	FA
12-28	Anniversary bonus dividend	FA
12-24	Chugai Pharmaceutical : Corporate Governance Report	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

MoU between Chugai, SoftBank and SB for joint research using generative AI

February 03, 2025 at 08:32 am